Compounding ban ‘a significant public health concern’

Government urged to roll back its ban on compounding weight loss drugs  Banning the compounding of glucagon-like peptide-2 receptor agonists (GLP-1RAs) medications will limit patient access to the weight loss treatments, the Australia Society of Compounding Pharmacists (ASCP) warns.   Responding to the government’s planned prohibition on compounding of the medications, the group called on

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Government acts on compounding concerns
Next A new era looms